A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

16386XL092-311-NCT06943755OpenA Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine TumorsXL092-311NCT06943755IndustrialAdultTreatmentII/IIINationalOtherNoel, MarcusGeorgetown University Medical Center : Susan Lawrence; Lombardi Comprehensive Cancer Center : Susan LawrenceGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC)17105Susan LawrenceSusan Lawrencesl2328@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>